ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pirfenidone

Also written as “Pirfenidone”, “Pirfenidone Modified-Release Tablets” and “Deupirfenidone”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Lung Injury · Lung Diseases, Interstitial · Pulmonary Fibrosis · COVID-19, led by 6 companies.

Drug pagePirfenidone: every studyMany companies study it; this page follows only the 29 they lead. All 102 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 4, 201529 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche120 open or runningphase 4since Nov 4, 2015Mar 24, 2004none ahead
GNI Groupits history only72 open or runningphase 3since Feb 26, 2019Nov 18, 2014Dec 30, 2026phase 3 · NCT07388680
PureTechits history only52 open or runningphase 3since Dec 8, 2025Jan 21, 2020Nov 2029phase 3 · NCT07284602
Overseas Pharmaceuticalsits history only30 open or runningphase 1since Aug 22, 2024Aug 22, 2024none ahead
beijing-kawin-technology-share-holding-co-ltdits history only10 open or runningphase 2since Dec 30, 2011Dec 30, 2011none ahead
grupo-medifarma-s-a-de-c-vits history only10 open or runningphase 3since Jul 6, 2015Jul 6, 2015none ahead

Also a collaborator on its studies: Clinipace Worldwide, Novotech (Australia) Pty, Shanghai Genomics and GNI-EPS Pharmaceuticals, Inc. (GNI Group).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2004First study: phase 2 study in Idiopathic Pulmonary FibrosisFirst studyNCT00080223 · 83 enrolled · United States
  2. Feb 6, 20062 phase 3 studies in Idiopathic Pulmonary FibrosisNCT00287729, NCT00287716
  3. Apr 17, 2008Phase 3 study in Idiopathic Pulmonary FibrosisNCT00662038 · 1,058 enrolled · United States
  4. Jun 2, 2011Phase 3 study in Idiopathic Pulmonary FibrosisNCT01366209 · 555 enrolled · United States
  5. Jun 5, 2013Phase 2 study in Idiopathic Pulmonary FibrosisNCT01872689 · 505 enrolled · United States, Australia, Belgium and more
  6. Aug 23, 2013Phase 2 study in Scleroderma, SystemicNCT01933334 · 63 enrolled · United States, Canada, Italy
  7. Aug 14, 2015Phase 1 study in Healthy VolunteerNCT02525484 · 44 enrolled · United States
  8. Nov 4, 2015Phase 4 study in Idiopathic Pulmonary FibrosisNCT02598193 · 89 enrolled · United States, Canada, Denmark and more
  9. Jan 5, 2016Phase 1 study in Idiopathic Pulmonary FibrosisNCT02648048 · 21 enrolled · United States, Germany
  10. Mar 31, 2017Phase 2 study in Lung Diseases, InterstitialNCT03099187 · 253 enrolled · Australia, Belgium, Canada and more
  11. Jun 26, 2017Phase 3 study in Idiopathic Pulmonary FibrosisNCT03208933 · 60 enrolled · Russian Federation

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03208933Idiopathic Pulmonary Fibrosis · Russian Federation3CompletedNov 13, 201960
NCT03099187Lung Diseases, Interstitial · Australia, Belgium, Canada and more2CompletedNov 21, 2018253
NCT02648048Idiopathic Pulmonary Fibrosis · United States, Germany1CompletedNov 30, 201621
NCT02598193Idiopathic Pulmonary Fibrosis · United States, Canada, Denmark and more4CompletedMay 16, 201789
NCT02525484Healthy Volunteer · United States1CompletedAug 201544
NCT01933334Scleroderma, Systemic · United States, Canada, Italy2CompletedSep 201463
NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more2CompletedJul 28, 2017505
NCT01366209Idiopathic Pulmonary Fibrosis · United States3CompletedFeb 2014555
NCT00662038Idiopathic Pulmonary Fibrosis · United States3CompletedFeb 20161,058
NCT00287729Idiopathic Pulmonary Fibrosis · United States3CompletedNov 2008344
NCT00287716Idiopathic Pulmonary Fibrosis · United States3CompletedNov 10, 2008435
NCT00080223Idiopathic Pulmonary Fibrosis · United States2CompletedApr 30, 201583

How it is read

Names in the registry

  • “Pirfenidone”, 26 entries
  • “Pirfenidone Modified-Release Tablets”, 4 entries
  • “Deupirfenidone”, 3 entries
  • “pirfenidone capsule”, 2 entries
  • “pirfenidone”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.